| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | DOK1; p62(dok); P62DOK; pp62;;DOK1 |
| WB Predicted band size | Calculated MW: 52 kDa ; Observed MW: 65 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human DOK1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于DOK1抗体的3篇参考文献示例(内容基于典型研究方向概括，非真实文献)：
1. **文献名称**：*DOK1 modulates T-cell signaling and regulates autoimmune inflammation*
**作者**：Smith A, et al.
**摘要**：研究通过DOK1抗体进行免疫沉淀和Western blot分析，发现DOK1在T细胞受体信号通路中负向调控MAPK激活，其缺失导致小鼠模型中出现自身免疫性炎症增强。
2. **文献名称**：*Downregulation of DOK1 in chronic lymphocytic leukemia correlates with disease progression*
**作者**：Chen L, et al.
**摘要**：利用DOK1抗体对白血病患者样本进行免疫组化检测，发现DOK1蛋白在慢性淋巴细胞白血病(CLL)中表达显著降低，且低表达与不良预后相关，提示其可能的肿瘤抑制功能。
3. **文献名称**：*DOK1 interacts with RasGAP to inhibit oncogenic Ras signaling in colorectal cancer*
**作者**：Wang Y, et al.
**摘要**：通过DOK1抗体介导的共聚焦显微镜和免疫共沉淀实验，揭示了DOK1与RasGAP形成复合物，抑制结直肠癌中Ras-MAPK通路的异常活化，为靶向治疗提供新思路。
4. **文献名称**：*Antibody-based detection of DOK1 phosphorylation as a biomarker for immune activation*
**作者**：Gomez-Ramos M, et al.
**摘要**：开发了一种特异性识别磷酸化DOK1的单克隆抗体，并验证其在流式细胞术中的应用，证实DOK1磷酸化水平可作为免疫细胞激活状态的动态标志物。
(注：以上文献信息为模拟生成，实际引用需查询PubMed等数据库获取真实研究。)
The DOK1 (Docking Protein 1) antibody is a tool used to detect and study the DOK1 protein, a member of the DOK family of adaptor proteins involved in intracellular signaling. DOK1. also known as p62dok, plays a critical role in regulating immune responses and cancer progression. It functions as a negative regulator of receptor tyrosine kinase (RTK) signaling pathways, including those activated by insulin, epidermal growth factor (EGF), and cytokines. Structurally, DOK1 contains a pleckstrin homology (PH) domain, a phosphotyrosine-binding (PTB) domain, and multiple tyrosine phosphorylation sites, enabling interactions with signaling molecules like RasGAP and PI3K.
In immune cells, DOK1 modulates T-cell receptor (TCR) and B-cell receptor (BCR) signaling, influencing cell activation, proliferation, and tolerance. Its downregulation or inactivation is linked to autoimmune diseases and malignancies, such as leukemia and lung cancer, where it often acts as a tumor suppressor. DOK1 antibodies are widely used in research applications like Western blotting, immunohistochemistry, and flow cytometry to investigate its expression, phosphorylation status, and interactions in cellular pathways. Studies utilizing these antibodies have highlighted DOK1's role in suppressing oncogenic signaling (e.g., Ras-MAPK, PI3K-Akt) and maintaining immune homeostasis, making it a potential therapeutic target. Dysregulation of DOK1 is also associated with metabolic disorders, emphasizing its broad physiological relevance.
×
